119 related articles for article (PubMed ID: 27933945)
1. Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA
Woolford AJ; Day PJ; Bénéton V; Berdini V; Coyle JE; Dudit Y; Grondin P; Huet P; Lee LY; Manas ES; McMenamin RL; Murray CW; Page LW; Patel VK; Potvain F; Rich SJ; Sang Y; Somers DO; Trottet L; Wan Z; Zhang X
J Med Chem; 2016 Dec; 59(23):10738-10749. PubMed ID: 27933945
[TBL] [Abstract][Full Text] [Related]
2. Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
Woolford AJ; Pero JE; Aravapalli S; Berdini V; Coyle JE; Day PJ; Dodson AM; Grondin P; Holding FP; Lee LY; Li P; Manas ES; Marino J; Martin AC; McCleland BW; McMenamin RL; Murray CW; Neipp CE; Page LW; Patel VK; Potvain F; Rich S; Rivero RA; Smith K; Somers DO; Trottet L; Velagaleti R; Williams G; Xie R
J Med Chem; 2016 Jun; 59(11):5356-67. PubMed ID: 27167608
[TBL] [Abstract][Full Text] [Related]
3. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Liu Q; Huang F; Yuan X; Wang K; Zou Y; Shen J; Xu Y
J Med Chem; 2017 Dec; 60(24):10231-10244. PubMed ID: 29193967
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Chen X; Xu W; Wang K; Mo M; Zhang W; Du L; Yuan X; Xu Y; Wang Y; Shen J
J Med Chem; 2015 Nov; 58(21):8529-41. PubMed ID: 26479945
[TBL] [Abstract][Full Text] [Related]
5. Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.
Huang F; Hu H; Wang K; Peng C; Xu W; Zhang Y; Gao J; Liu Y; Zhou H; Huang R; Li M; Shen J; Xu Y
J Med Chem; 2020 Jul; 63(13):7052-7065. PubMed ID: 32459096
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies.
Grädler U; Schwarz D; Blaesse M; Leuthner B; Johnson TL; Bernard F; Jiang X; Marx A; Gilardone M; Lemoine H; Roche D; Jorand-Lebrun C
Bioorg Med Chem Lett; 2019 Dec; 29(23):126717. PubMed ID: 31635932
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.
Chen X; Wang K; Xu W; Ma Q; Chen M; Du L; Mo M; Wang Y; Shen J
J Med Chem; 2016 Mar; 59(6):2674-87. PubMed ID: 26927682
[TBL] [Abstract][Full Text] [Related]
8. Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.
Wang K; Xu W; Zhang W; Mo M; Wang Y; Shen J
Bioorg Med Chem Lett; 2013 May; 23(10):2897-901. PubMed ID: 23575276
[TBL] [Abstract][Full Text] [Related]
9. (E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors.
Jeong TS; Kim MJ; Yu H; Kim KS; Choi JK; Kim SS; Lee WS
Bioorg Med Chem Lett; 2005 Mar; 15(5):1525-7. PubMed ID: 15713421
[TBL] [Abstract][Full Text] [Related]
10. Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
Liu Q; Chen X; Chen W; Yuan X; Su H; Shen J; Xu Y
J Med Chem; 2016 May; 59(10):5115-20. PubMed ID: 27078579
[TBL] [Abstract][Full Text] [Related]
11. Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE).
Boy KM; Guernon JM; Shi J; Toyn JH; Meredith JE; Barten DM; Burton CR; Albright CF; Marcinkeviciene J; Good AC; Tebben AJ; Muckelbauer JK; Camac DM; Lentz KA; Bronson JJ; Olson RE; Macor JE; Thompson LA
Bioorg Med Chem Lett; 2011 Nov; 21(22):6916-24. PubMed ID: 21782431
[TBL] [Abstract][Full Text] [Related]
12. Natural product derived inhibitors of lipoprotein associated phospholipase A2, synthesis and activity of analogues of SB-253514.
Pinto IL; Boyd HF; Hickey DM
Bioorg Med Chem Lett; 2000 Sep; 10(17):2015-7. PubMed ID: 10987439
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A2.
McConnell JP; Hoefner DM
Clin Lab Med; 2006 Sep; 26(3):679-97, vii. PubMed ID: 16938590
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors.
Pemberton N; Mogemark M; Arlbrandt S; Bold P; Cox RJ; Gardelli C; Holden NS; Karabelas K; Karlsson J; Lever S; Li X; Lindmark H; Norberg M; Perry MWD; Petersen J; Rodrigo Blomqvist S; Thomas M; Tyrchan C; Westin Eriksson A; Zlatoidsky P; Öster L
J Med Chem; 2018 Jun; 61(12):5435-5441. PubMed ID: 29852070
[TBL] [Abstract][Full Text] [Related]
15. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
Tellis CC; Tselepis AD
Biochim Biophys Acta; 2009 May; 1791(5):327-38. PubMed ID: 19272461
[TBL] [Abstract][Full Text] [Related]
16. Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents.
Andrews DM; Chaignot H; Coomber BA; Good AC; Hind SL; Johnson MR; Jones PS; Mills G; Robinson JE; Skarzynski T; Slater MJ; Somers DO
Org Lett; 2002 Dec; 4(25):4479-82. PubMed ID: 12465917
[TBL] [Abstract][Full Text] [Related]
17. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.
Zalewski A; Macphee C
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):923-31. PubMed ID: 15731492
[TBL] [Abstract][Full Text] [Related]
18. Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.
Shi Y; Zhang J; Shi M; O'Connor SP; Bisaha SN; Li C; Sitkoff D; Pudzianowski AT; Chong S; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2009 Aug; 19(15):4034-41. PubMed ID: 19541481
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study.
Garg PK; Arnold AM; Hinckley Stukovsky KD; Koro C; Jenny NS; Mukamal KJ; Criqui MH; Furberg CD; Newman AB; Cushman M
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):750-6. PubMed ID: 26848158
[TBL] [Abstract][Full Text] [Related]
20. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
